Treating patients with lupus with B-cell depletion

被引：13

作者：

Isenberg, D. A. ^{[1
]}

机构：

[1] UCL, Ctr Rheumatol, Div Med, London W1T 4JF, England

来源：

LUPUS | 2008年 / 17卷 / 05期

关键词：

D O I：

10.1177/0961203308090024

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A new era in the treatment of systemic lupus erythematosus has dawned with the increasing introduction of monoclonal antibodies and other approaches, that target the key molecules involved in the pathogenesis of the disease. At present the ability to block the CD20 molecule on those B cells that carry this marker has proved the most effective way to treat patients resistant to conventional immunosuppressive drugs. However, these studies have all been open label and the results of double blind controlled studies are eagerly awaited.

引用

页码：400 / 404

页数：5

共 27 条

[11] Treatment of refractory SLE with rituximab plus cyclophosphamide:: clinical effects, serological changes, and predictors of response [J].

Jonsdottir, T. ;

Gunnarsson, I. ;

Risselada, A. ;

Henriksson, E. W. ;

Klareskog, L. ;

van Vollenhoven, R. F. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) :330-334

[12] Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus [J].

Ju, Shaoqing ;

Zhang, Donglei ;

Wang, Yueguo ;

Ni, Hongbing ;

Kong, Xiantao ;

Zhong, Renqian .

CLINICAL BIOCHEMISTRY, 2006, 39 (12) :1131-1137

[13] B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients [J].

Leandro, MJ ;

Cambridge, G ;

Edwards, JC ;

Ehrenstein, MR ;

Isenberg, DA .

RHEUMATOLOGY, 2005, 44 (12) :1542-1545

[14] An open study of B lymphocyte depletion in systemic lupus erythematosus [J].

Leandro, MJ ;

Edwards, JC ;

Cambridge, G ;

Ehrenstein, MR ;

Isenberg, DA .

ARTHRITIS AND RHEUMATISM, 2002, 46 (10) :2673-2677

[15] B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab [J].

Looney, RJ ;

Anolik, JH ;

Campbell, D ;

Felgar, RE ;

Young, F ;

Arend, LJ ;

Sloand, JA ;

Rosenblatt, J ;

Sanz, I .

ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2580-2589

[16] BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator [J].

Moore, PA ;

Belvedere, O ;

Orr, A ;

Pieri, K ;

LaFleur, DW ;

Feng, P ;

Soppet, D ;

Charters, M ;

Gentz, R ;

Parmelee, D ;

Li, YL ;

Galperina, O ;

Giri, J ;

Roschke, V ;

Nardelli, B ;

Carrell, J ;

Sosnovtseva, S ;

Greenfield, W ;

Ruben, SM ;

Olsen, HS ;

Fikes, J ;

Hilbert, DM .

SCIENCE, 1999, 285 (5425) :260-263

[17] Repeated B cell depletion in treatment of refractory systemic lupus erythematosus [J].

Ng, K. P. ;

Leandro, M. J. ;

Edwards, J. C. ;

Ehrenstein, M. R. ;

Cambridge, G. ;

Isenberg, D. A. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (07) :942-945

[18] B cell depletion therapy in systemic lupus erythematosus: Longterm follow-up and predictors of response [J].

Ng, Kristine P. ;

Cambridge, Geraldine ;

Leandro, Maria J. ;

Edwards, Jonathan C. W. ;

Ehrenstein, Michael ;

Isenberg, David A. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) :1259-1262

[19]

REFF ME, 1994, BLOOD, V83, P435

[20] BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases [J].

Roschke, V ;

Sosnovtseva, S ;

Ward, CD ;

Hong, JS ;

Smith, R ;

Albert, V ;

Stohl, W ;

Baker, KP ;

Ullrich, S ;

Nardelli, B ;

Hilbert, DM ;

Migone, TS .

JOURNAL OF IMMUNOLOGY, 2002, 169 (08) :4314-4321

← 1 2 3 →